Lithium and Acetate for Canavan Disease
Primary Purpose
Canavan Disease, Infantile, Deficiency Disease
Status
Withdrawn
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
Lithium Gluconate (drug) Glyceryl Triacetate GTA (drug)
Sponsored by
About this trial
This is an interventional treatment trial for Canavan Disease focused on measuring Leukodystrophy, Canavan disease,, Aspartoacylase,, Lithium,, Glyceryl Triacetate
Eligibility Criteria
Inclusion Criteria:
- Clinical and biochemical diagnosis of Canavan disease
Exclusion Criteria:
- Renal disease
- Thyroid disease
- Cardiac disease
- Impossibility to perform brain MRI
Sites / Locations
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
1
Arm Description
Outcomes
Primary Outcome Measures
The primary outcome will be a decrease of the NAA peak (> 20%) or the appearance of an acetate peak at the end of the treatment (10 months), using spectroscopy-MRI.
Secondary Outcome Measures
Secondary outcomes will be assessed at 10 months (end of the treatment): -Improvement of neuromotor performances (GMFM and Mullen scales), spasticity, and neurological severity
-Improvement of epilepsy (number of seizures)
-Decrease in NAA and increase in acetate contents in fluids (CSF, plasma, urine).
Full Information
NCT ID
NCT00657748
First Posted
April 9, 2008
Last Updated
April 20, 2015
Sponsor
Assistance Publique - Hôpitaux de Paris
Collaborators
European Leukodystrophy Association
1. Study Identification
Unique Protocol Identification Number
NCT00657748
Brief Title
Lithium and Acetate for Canavan Disease
Official Title
Evaluation of the Tolerance and Efficiency of a Combined Oral Therapy With Lithium and GTA in Patients With Canavan Disease
Study Type
Interventional
2. Study Status
Record Verification Date
April 2015
Overall Recruitment Status
Withdrawn
Study Start Date
September 2009 (undefined)
Primary Completion Date
September 2010 (Actual)
Study Completion Date
January 2011 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
Assistance Publique - Hôpitaux de Paris
Collaborators
European Leukodystrophy Association
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The aim of this study is to determine whether oral supplementation with lithium and acetate may improve the biological and clinical prognosis in patients with Canavan Disease.
Detailed Description
Canavan Disease is an autosomal recessive devastating demyelinating disease caused by a deficiency in Aspartoacylase (ASPA) enzyme. There is no available treatment. ASPA deficiency leads to:- the accumulation of high levels of N-acetylaspartate (NAA), involved in myelin degeneration and epilepsy;- the deficient synthesis of acetate in oligodendrocytes, that could impair CNS myelination.Lithium administration induces a decrease in NAA in the brain of the tremor rats (animal model for CD) and in one patient (JANSON, 2005). On the other hand, administration of acetate could improve myelination in Canavan patients.For this reason, we propose to combine both treatments: Lithium Gluconate and Glyceryl Triacetate (GTA). Eighteen patients, aged 1 to 15 years, will receive oral GTA or Lithium during 4 months, then both treatment in association during 6 months. Patients will be sequentially evaluated up to the end of the treatment and 2 months thereafter for:-tolerance of the therapy (careful monitoring of clinical and biological parameters).- efficacy of the therapy on clinical, biological and radiological parameters. Particularly, we will evaluate using MRI-spectroscopy and CSF samples the decrease in NAA and increase in acetate levels in the brain.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Canavan Disease, Infantile, Deficiency Disease, Aspartoacylase, Leukodystrophy, Spongiform
Keywords
Leukodystrophy, Canavan disease,, Aspartoacylase,, Lithium,, Glyceryl Triacetate
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
1
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
Lithium Gluconate (drug) Glyceryl Triacetate GTA (drug)
Other Intervention Name(s)
Lithium Gluconate (drug), Glyceryl Triacetate, GTA (drug)
Intervention Description
Lithium 1.3 mEq/kg/day (three administrations a day)during the study GTA 500 mg/kg/day in four administrations a day during the study
Primary Outcome Measure Information:
Title
The primary outcome will be a decrease of the NAA peak (> 20%) or the appearance of an acetate peak at the end of the treatment (10 months), using spectroscopy-MRI.
Time Frame
10 months
Secondary Outcome Measure Information:
Title
Secondary outcomes will be assessed at 10 months (end of the treatment): -Improvement of neuromotor performances (GMFM and Mullen scales), spasticity, and neurological severity
Time Frame
10 months
Title
-Improvement of epilepsy (number of seizures)
Time Frame
10 months
Title
-Decrease in NAA and increase in acetate contents in fluids (CSF, plasma, urine).
Time Frame
10 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
1 Year
Maximum Age & Unit of Time
15 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Clinical and biochemical diagnosis of Canavan disease
Exclusion Criteria:
Renal disease
Thyroid disease
Cardiac disease
Impossibility to perform brain MRI
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Patrick Aubourg, MD, PhD
Organizational Affiliation
Assistance Publique - Hôpitaux de Paris
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Caroline Sevin, MD, PhD
Organizational Affiliation
Assistance Publique - Hôpitaux de Paris
Official's Role
Principal Investigator
12. IPD Sharing Statement
Citations:
PubMed Identifier
16002461
Citation
Mathew R, Arun P, Madhavarao CN, Moffett JR, Namboodiri MA. Progress toward acetate supplementation therapy for Canavan disease: glyceryl triacetate administration increases acetate, but not N-acetylaspartate, levels in brain. J Pharmacol Exp Ther. 2005 Oct;315(1):297-303. doi: 10.1124/jpet.105.087536. Epub 2005 Jul 7.
Results Reference
result
PubMed Identifier
15784740
Citation
Madhavarao CN, Arun P, Moffett JR, Szucs S, Surendran S, Matalon R, Garbern J, Hristova D, Johnson A, Jiang W, Namboodiri MA. Defective N-acetylaspartate catabolism reduces brain acetate levels and myelin lipid synthesis in Canavan's disease. Proc Natl Acad Sci U S A. 2005 Apr 5;102(14):5221-6. doi: 10.1073/pnas.0409184102. Epub 2005 Mar 22.
Results Reference
result
PubMed Identifier
16194720
Citation
Janson CG, Assadi M, Francis J, Bilaniuk L, Shera D, Leone P. Lithium citrate for Canavan disease. Pediatr Neurol. 2005 Oct;33(4):235-43. doi: 10.1016/j.pediatrneurol.2005.04.015.
Results Reference
result
PubMed Identifier
12064356
Citation
Baslow MH, Kitada K, Suckow RF, Hungund BL, Serikawa T. The effects of lithium chloride and other substances on levels of brain N-acetyl-L-aspartic acid in Canavan disease-like rats. Neurochem Res. 2002 May;27(5):403-6. doi: 10.1023/a:1015504031229.
Results Reference
result
Links:
URL
http://www.ela-asso.com/
Description
ELA (European Leukodystrophy Association)
Learn more about this trial
Lithium and Acetate for Canavan Disease
We'll reach out to this number within 24 hrs